Fountain Life's '3.4% occult cancer' is a vendor number, not an independent finding

Why it matters (spine — hype). The hype ledger — kept on purpose, as the discipline. Treat vendor screening percentages as marketing until a cohort methodology is published; build MKG's independent 'validated vs hyped' audit as the product.

What would prove it wrong (falsifier). Fountain Life publishes a peer-reviewed cohort with denominators and outcomes that substantiate the rate and a mortality benefit.

Live-status check + triangulation. The episode's striking 'we find cancer in 3.3% of healthy members' is Fountain Life's own self-reported figure ('up to 3.4%,' PR 2026-01-06) — no disclosed denominator, no peer review, and a clear commercial interest. Held against the rigorous comparator already carded (the NHS-Galleri MCED RCT, n≈142,000, which missed its primary endpoint), and GRAIL's Galleri getting Medicare coverage (2026-02-03) before FDA approval, this is the validated-vs-hyped line the measurement layer exists to police. Screening finds indolent disease too; a found cancer is not always a life saved. Source: Company PR · Fountain Life (contrarian ledger) (2026-01-06); see source link. Every post-cutoff figure was tool-fetched against a live source during the Kimi K3 sweep (2026-07-20); see sweeps/2026-07-20-VERIFIED_DIGEST.md for the full provenance and any corrections of record.